Anthem Biosciences Ltd (ANTHEM) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- Anthem Biosciences reported strong consolidated revenue growth for the first half of FY26, reaching INR 1090 crores, driven by robust performance in its CRDMO business.
- The company achieved a significant EBITDA of INR 480 crores, reflecting a healthy margin of 41.4%, indicating effective cost management and operational leverage.
- Net cash position improved substantially to INR 990 crores by the end of September 30th, demonstrating strong cash generation and financial health.
- The CRDMO business was a primary growth driver, delivering INR 926 crores in revenue, while the specialty ingredients business experienced a temporary decline due to fungible capacity allocation.
- Anthem Biosciences continues to expand its commercial product portfolio, with 14 molecules now commercialized, up from 10 at the time of IPO, showcasing successful pipeline progression.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.